Page last updated: 2024-08-23

idarubicin and Hormone-Dependent Neoplasms

idarubicin has been researched along with Hormone-Dependent Neoplasms in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (50.00)	18.2507
2000's	1 (50.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Akçali, Z; Boğa, S; DemIrhan, B; Karakuş, S; Sahin, FI; Yilmaz, Z	1
Bernhard, J; Castiglione, M; Gusset, H; Hanselmann, S; Hering, F; Maibach, R; Morant, R; Pestalozzi, D; Schmid, HP	1

Trials

1 trial(s) available for idarubicin and Hormone-Dependent Neoplasms

Article	Year
A phase II study of oral idarubicin as a treatment for metastatic hormone-refractory prostate carcinoma with special focus on prostate specific antigen doubling time. Swiss Group for Clinical Cancer Research, Berne, Switzerland. Cancer, 1997, May-01, Volume: 79, Issue:9 Topics: Administration, Oral; Aged; Antibiotics, Antineoplastic; Drug Resistance, Neoplasm; Humans; Idarubicin; Male; Middle Aged; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Prostate-Specific Antigen; Prostatic Neoplasms	1997

Article

Year

A phase II study of oral idarubicin as a treatment for metastatic hormone-refractory prostate carcinoma with special focus on prostate specific antigen doubling time. Swiss Group for Clinical Cancer Research, Berne, Switzerland.

Cancer, 1997, May-01, Volume: 79, Issue:9

Topics: Administration, Oral; Aged; Antibiotics, Antineoplastic; Drug Resistance, Neoplasm; Humans; Idarubicin; Male; Middle Aged; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Prostate-Specific Antigen; Prostatic Neoplasms

1997

Other Studies

1 other study(ies) available for idarubicin and Hormone-Dependent Neoplasms

Article	Year
t(8;16) AML developed subsequent to breast cancer therapy. Hematology (Amsterdam, Netherlands), 2006, Volume: 11, Issue:3 Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Chromosomes, Human, Pair 16; Chromosomes, Human, Pair 8; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Doxorubicin; Estrogens; Fatal Outcome; Female; Fluorouracil; Humans; Idarubicin; Leukemia, Myelomonocytic, Acute; Mastectomy, Modified Radical; Middle Aged; Neoplasms, Hormone-Dependent; Neoplasms, Multiple Primary; Neoplasms, Second Primary; Nitriles; Radiotherapy, Adjuvant; Translocation, Genetic; Triazoles	2006

Article

Year

t(8;16) AML developed subsequent to breast cancer therapy.

Hematology (Amsterdam, Netherlands), 2006, Volume: 11, Issue:3

Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Chromosomes, Human, Pair 16; Chromosomes, Human, Pair 8; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Doxorubicin; Estrogens; Fatal Outcome; Female; Fluorouracil; Humans; Idarubicin; Leukemia, Myelomonocytic, Acute; Mastectomy, Modified Radical; Middle Aged; Neoplasms, Hormone-Dependent; Neoplasms, Multiple Primary; Neoplasms, Second Primary; Nitriles; Radiotherapy, Adjuvant; Translocation, Genetic; Triazoles

2006